NRAS and acute myeloid leukemia: A substantial proportion of AML patient samples tested (14 out of 30 samples) were classified as sustained responders to imetelstat monotherapy and are characterized by genetic lesions in genes involved in cell adhesion, metabolism and signaling, with the most striking result obtained for NRAS. NRAS is the fourth most commonly observed gene with driver mutations in adult AML2.